No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Tango Therapeutics To Highlight Preclinical Data On Precision Oncology Pipeline With Five Posters At American Association for Cancer Research Annual Meeting 2025
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Tango Therapeutics (TNGX) Receives a Buy From Barclays
Lacklustre Performance Is Driving Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 30% Price Drop
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint
Tango Therapeutics Advances Cancer Treatment Pipeline